Adaptimmune Therapeutics PLC (ADAPY) vs Tempest Therapeutics, Inc. (TPST)

Adaptimmune Therapeutics PLC and Tempest Therapeutics, Inc. are both Biotechnology companies. Adaptimmune Therapeutics PLC and Tempest Therapeutics, Inc. are of similar size ($14.6M and $14.4M). Tempest Therapeutics, Inc. grew revenue faster over the last twelve months: −53.0% against −54.0%. Tempest Therapeutics, Inc. has the higher net margin (0.00% vs −262.5%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Tempest Therapeutics, Inc. leads on 8 and Adaptimmune Therapeutics PLC on 7.

Valuation

Metric ADAPY TPST Biotechnology median
P/E n/m n/m 7.88
P/S 0.12 39.00 11.47
P/B n/m n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 0.12 52.83 10.73
Earnings yield (2,166.67%) (515.66%) (28.84%)
Free cash flow yield (2,380.45%) (167.50%) (23.03%)

Profitability

Metric ADAPY TPST Biotechnology median
Gross margin 94.81% 0.00% 65.16%
Operating margin (427.75%) 0.00% 0.00%
Net margin (262.46%) 0.00% 0.00%
Free cash flow margin (288.20%) 0.00% 0.00%
Return on equity (1,349.52%) (931.14%) (57.72%)
Return on assets 0.00% (237.25%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ADAPY TPST Biotechnology median
Revenue growth (TTM) (53.99%) (52.98%) 5.64%
EPS growth (last fiscal year) 142.86% 67.55% —
Revenue growth, 5-year CAGR 8.40% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ADAPY TPST Biotechnology median
Debt to equity (0.36) 0.00 0.00
Current ratio 1.52 0.38 4.73
Net debt to EBITDA 0.47 0.29 0.96

Dividend

Metric ADAPY TPST Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ADAPY TPST Biotechnology median
Market cap 14.55m 14.39m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack